New antibody drug tested in patients with advanced stomach and gut cancers
Disease control
Terminated
This early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …
Phase: PHASE1 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC